NasdaqCM - Nasdaq Real Time Price USD

Alzamend Neuro, Inc. (ALZN)

3.9387

+0.4387

+(12.49%)

As of 3:34:33 PM EDT. Market Open.

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’

GlobeNewswire 5 days ago

ALZN
+12.49%
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Massachusetts General Hospital Main Entrance Massachusetts General Hospital Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’

GlobeNewswire 15 days ago

ALZN
+12.49%
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorde

GlobeNewswire 21 days ago

ALZN
+12.49%
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore AL001 and its potential to deliver lithium more effectively in the brain than marketed lithium sa

Benzinga 21 days ago

ALZN
+12.49%
Alzamend Neuro Announces Reverse Stock Split

ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that Alzamend’s board of directors approved a one-for-nine reverse stock split of Alzamend’s common stock (“Common Stock”) that will

GlobeNewswire 26 days ago

ALZN
+12.49%
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stre

GlobeNewswire 27 days ago

ALZN
+12.49%
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced its partnership with Mint Labs Inc. d/b/a QMENTA, a medical imaging artificial intelligence company, to support its five upcoming Phase 2 trials of AL001 at Massachusetts General Hospital. QMENTA's cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management. Also Read: EXCLUSIVE: Alzamend Neuro To Start First Phase

Benzinga 27 days ago

ALZN
+12.49%
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks last month

ALZN
+12.49%
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Alzamend Neuro, Inc. (NASDAQ:ALZN) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]

Insider Monkey 2 months ago

ALZN
+12.49%

COMP
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjectsATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic

GlobeNewswire 2 months ago

ALZN
+12.49%
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress

GlobeNewswire 2 months ago

ALZN
+12.49%
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects Approx 1 in 13 People in the US PTSD Approximately 1 in 13 people in the US will develop PTSD in their lifetime. All rights reserved; proprietary content owned by Alzamend Neuro, Inc. 9 Million Americans Live w PTSD It is estimated that 9 Million Americans are currently living with PTSD while women are 2 times mor

GlobeNewswire 2 months ago

ALZN
+12.49%
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects Bipolar Disorder Statement Over 7 Million Americans are projected to be living with Bipolar Disorder.Bipolar disorder (BD) is a medical condition that causes dramatic shifts in a person's mood, energy, and ability to think clearly.@2025 all rights reserved, property of Alzamend Neuro, Inc. Bipolar Diso

GlobeNewswire 2 months ago

ALZN
+12.49%
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjectsATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumati

GlobeNewswire 3 months ago

ALZN
+12.49%
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025

On Tuesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The first study, in healthy human subjects, is expected to commence in the second quarter of 2025. The study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. The head coil will capture detailed images of lithium across the entire brain, making measuring its levels in different brain regions easier and hel

Benzinga 3 months ago

ALZN
+12.49%
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

ATLANTA, February 19, 2025--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials

Business Wire 3 months ago

ALZN
+12.49%
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels

On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced it had completed the head coil by Tesla Dynamic Coils BV. The development of the head coil was necessary to facilitate Alzamend's five upcoming Phase 2 clinical trials. In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend intends to undertake clinical trials to assess how lithium levels in the brain differ when using AL001 compared to marketed lithium salts, both in healthy individuals and

Benzinga 3 months ago

ALZN
+12.49%
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to their sector so far this year.

Zacks 4 months ago

ALZN
+12.49%

BEAM
Alzamend Neuro to Present at the Sequire Investor Summit

ATLANTA, January 15, 2025--Alzamend Neuro to Present at Sequire Investor Summit; Company to Report Progress with Clinical Trials to be Initiated in 2025 and Expected Milestones

Business Wire 4 months ago

ALZN
+12.49%
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

ATLANTA, December 18, 2024--Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo; Topic is Pharmacokinetics of AL001

Business Wire 5 months ago

ALZN
+12.49%

Performance Overview

Return	ALZN	S&P 500 (^GSPC)
YTD	-62.27%	+1.55%
1-Year	-92.45%	+13.05%
3-Year	-99.70%	+45.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Alzamend Neuro to Present at the Sequire Investor Summit

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Performance Overview